



LipiFlow is the only FDA-cleared electronic medical device for Meibomian Gland Dysfunction (MGD) shown to restore gland function. LipiFlow's Vectored Thermal Pulse™ (VTP) technology applies simultaneous heat and pressure to the eyelid to remove gland contents and obstructions while at the same time protecting delicate structures of the patient's eye.

- A single-use sterile LipiFlow Activator directs simultaneous heat and pulsed pressure to target the meibomian glands during a 12-minute in-office procedure.
- LipiFlow utilizes patented inner-lid heating with redundant mechanical and electronic safety measures.
- A phased pressure profile with adaptive force equalization and proximal to distal peristaltic motion evacuates gland contents.
- The drug-free mechanism of action is the result of over 10 years of dedicated research and 36 patents

A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DEMONSTRATED THAT FOR
86% of patients who received only a single LipiFlow treatment over 12 months, **MEAN IMPROVEMENT IN MEIBOMIAN GLAND FUNCTION AND DRY EYE SYMPTOMS WAS SUSTAINED FROM 1 MONTH THROUGH 12 MONTHS**¹

OVER 31 **PEER REVIEWED** Reports Demonstrated Efficacy²

¹Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016;10:1385-1396.

²Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Blackie C, Carlson AN, Korb DR Current Opinion in Ophthalmology. 2015 Jul;26(4):306-13.

Potential adverse effects that may occur as a result of the LipiFlow procedure include, but are not limited to, the onset or increase in:

- Eyelid/eye pain
- Eyelid irritation or inflammation
- Ocular surface irritation or inflammation
- Ocular symptoms